Trial Outcomes & Findings for Randomized Controlled Trial of Wellness Recovery Action Planning (NCT NCT01024569)

NCT ID: NCT01024569

Last Updated: 2020-01-10

Results Overview

The BSI is a patient self-report mental health symptoms research instrument (Piersma et al., 1994). Respondents are asked how much they were bothered in the past week by 53 symptoms on 9 dimensions with a 5-point response scale ranging from ''not at all'' to ''extremely.'' We assessed the BSI Positive Symptom Score which captures the number of symptoms endorsed in a pathological direction, representing the total volume of different symptoms reported to be present to any degree. The minimum value is 0 and the maximum score is 212, where higher scores mean a worse outcome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

555 participants

Primary outcome timeframe

Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

Results posted on

2020-01-10

Participant Flow

Participant milestones

Participant milestones
Measure
Wellness Recovery Action Planning (WRAP)
WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues. Wellness Recovery Action Planning (WRAP): WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
Comparison Wait-List Group
Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
Overall Study
STARTED
276
279
Overall Study
COMPLETED
251
268
Overall Study
NOT COMPLETED
25
11

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Randomized Controlled Trial of Wellness Recovery Action Planning

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Wellness Recovery Action Planning (WRAP)
n=251 Participants
WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues. Wellness Recovery Action Planning (WRAP): WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
Comparison Wait-List Group
n=268 Participants
Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
Total
n=519 Participants
Total of all reporting groups
Age, Continuous
45.7 years
STANDARD_DEVIATION 9.8 • n=5 Participants
45.8 years
STANDARD_DEVIATION 9.9 • n=7 Participants
45.8 years
STANDARD_DEVIATION 9.8 • n=5 Participants
Sex: Female, Male
Female
168 Participants
n=5 Participants
174 Participants
n=7 Participants
342 Participants
n=5 Participants
Sex: Female, Male
Male
83 Participants
n=5 Participants
94 Participants
n=7 Participants
177 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
6 Participants
n=5 Participants
9 Participants
n=7 Participants
15 Participants
n=5 Participants
Race (NIH/OMB)
Asian
2 Participants
n=5 Participants
1 Participants
n=7 Participants
3 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
76 Participants
n=5 Participants
70 Participants
n=7 Participants
146 Participants
n=5 Participants
Race (NIH/OMB)
White
167 Participants
n=5 Participants
186 Participants
n=7 Participants
353 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
2 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
251 participants
n=5 Participants
268 participants
n=7 Participants
519 participants
n=5 Participants
Study Site
Canton
38 Participants
n=5 Participants
43 Participants
n=7 Participants
81 Participants
n=5 Participants
Study Site
Cleveland
51 Participants
n=5 Participants
47 Participants
n=7 Participants
98 Participants
n=5 Participants
Study Site
Columbus
52 Participants
n=5 Participants
55 Participants
n=7 Participants
107 Participants
n=5 Participants
Study Site
Dayton
12 Participants
n=5 Participants
14 Participants
n=7 Participants
26 Participants
n=5 Participants
Study Site
Lorain
53 Participants
n=5 Participants
57 Participants
n=7 Participants
110 Participants
n=5 Participants
Study Site
Toledo
45 Participants
n=5 Participants
52 Participants
n=7 Participants
97 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Schizophrenia
29 Participants
n=5 Participants
29 Participants
n=7 Participants
58 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Schizoaffective
26 Participants
n=5 Participants
21 Participants
n=7 Participants
47 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Bipolar
95 Participants
n=5 Participants
93 Participants
n=7 Participants
188 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Depressive
60 Participants
n=5 Participants
65 Participants
n=7 Participants
125 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Other
34 Participants
n=5 Participants
42 Participants
n=7 Participants
76 Participants
n=5 Participants
Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-IV) Diagnosis
Missing
7 Participants
n=5 Participants
18 Participants
n=7 Participants
25 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

The BSI is a patient self-report mental health symptoms research instrument (Piersma et al., 1994). Respondents are asked how much they were bothered in the past week by 53 symptoms on 9 dimensions with a 5-point response scale ranging from ''not at all'' to ''extremely.'' We assessed the BSI Positive Symptom Score which captures the number of symptoms endorsed in a pathological direction, representing the total volume of different symptoms reported to be present to any degree. The minimum value is 0 and the maximum score is 212, where higher scores mean a worse outcome.

Outcome measures

Outcome measures
Measure
Experimental
n=251 Participants
Received intervention
Control
n=268 Participants
Did not receive intervention
Psychiatric Symptoms Recovery Using the Brief Symptoms Inventory (BSI)
Baseline
20.6 symptom severity score
Standard Deviation 14.67
19.29 symptom severity score
Standard Deviation 14.09
Psychiatric Symptoms Recovery Using the Brief Symptoms Inventory (BSI)
Postintervention 1
19.52 symptom severity score
Standard Deviation 13.74
21.38 symptom severity score
Standard Deviation 13.68
Psychiatric Symptoms Recovery Using the Brief Symptoms Inventory (BSI)
Postintervention 2
12.20 symptom severity score
Standard Deviation 15.22
12.65 symptom severity score
Standard Deviation 15.00

PRIMARY outcome

Timeframe: Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

Population: The Overall Number of Participants Analyzed reflects the number of participants at Time 1/Baseline.

Hopefulness is measured by the State Hope Scale. Hopefulness as a cross-situational long-term trait is assessed via patient self-report using a 12-item scale assessed on a 4-point Likert response scale with options ranging from "definitely false" to "definitely true" and summed to produce a total score and sub-scale scores. The minimum value for this scale is 12 and the maximum value is 48. Higher scores indicate a better income.

Outcome measures

Outcome measures
Measure
Experimental
n=248 Participants
Received intervention
Control
n=264 Participants
Did not receive intervention
Hopefulness
Baseline
21.67 Score on a Scale
Standard Deviation 4.66
21.87 Score on a Scale
Standard Deviation 4.42
Hopefulness
Post-intervention 1
22.47 Score on a Scale
Standard Deviation 4.39
22.07 Score on a Scale
Standard Deviation 4.06
Hopefulness
Post-intervention 2
22.76 Score on a Scale
Standard Deviation 4.68
22.16 Score on a Scale
Standard Deviation 4.21

PRIMARY outcome

Timeframe: Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

Population: The Overall Number of Participants Analyzed reflects the number of participants at Time 1/Baseline

The ability to advocate for oneself with medical care providers is assessed via self-report using The Patient Self-Advocacy Scale, an 18-item scale with a 5-point Likert response set ranging from "strongly disagree" to "strongly agree". Dimensions include in patient knowledge, assertiveness, and potential for mindful non-adherence to treatment. Values range from a minimum of 18 to a maximum of 90, with higher scores indicating a better outcome.

Outcome measures

Outcome measures
Measure
Experimental
n=251 Participants
Received intervention
Control
n=268 Participants
Did not receive intervention
Patient Self-Advocacy
Baseline (Time 1)
3.47 Score on a Scale
Standard Error 0.50
3.46 Score on a Scale
Standard Error 0.53
Patient Self-Advocacy
Post-intervention 1 (Time 2)
3.61 Score on a Scale
Standard Error 0.52
3.53 Score on a Scale
Standard Error 0.53
Patient Self-Advocacy
Post-intervention 2 (Time 3)
3.65 Score on a Scale
Standard Error 0.52
3.55 Score on a Scale
Standard Error 0.49

PRIMARY outcome

Timeframe: Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

Population: The Overall Number of Participants Analyzed reflects the number of participants at Time 1/Baseline.

This outcome is measured by the Recovery Assessment Scale (RAS). Recovery is a psychosocial outcome assessed via patient self-ratings on a 41-item scale using a 5-point Likert-Response format ranging from "strongly disagree" to "strongly agree". The minimum value for the RAS is 41 and the maximum is 205, with higher scores indicating a better outcome. Dimensions of recovery include personal confidence and hope, willingness to ask for help, goal and success orientation, reliance on others, and not being dominated by one's residual psychiatric symptoms.

Outcome measures

Outcome measures
Measure
Experimental
n=248 Participants
Received intervention
Control
n=265 Participants
Did not receive intervention
Recovery From Mental Illness
Baseline (Time 1)
88.2 score on a scale
Standard Deviation 14.9
87.4 score on a scale
Standard Deviation 13.2
Recovery From Mental Illness
Post-intervention 1 (Time 2)
92.9 score on a scale
Standard Deviation 14.2
90.0 score on a scale
Standard Deviation 13.7
Recovery From Mental Illness
Post-intervention 2 (Time 3)
93.7 score on a scale
Standard Deviation 14.7
91.2 score on a scale
Standard Deviation 13.1

SECONDARY outcome

Timeframe: Study entry (pre-intervention), 8-weeks later (post-intervention), & 6-months after intervention (approx. 8 months after study entry)

Population: The Overall Number of Participants Analyzed reflects the number of participants at Time 1

Quality of Life was assessed by the World Health Organization Quality of Life Brief Assessment (WHOQOL-BREF). The 8-item environment sub-scale was utilized for our study. Respondents rate their experience of 8 quality indicators over the past 2 weeks using a 5-point Likert response scale. The minimum value is 8 and the maximum is 40, with higher scores meaning better outcomes.

Outcome measures

Outcome measures
Measure
Experimental
n=251 Participants
Received intervention
Control
n=268 Participants
Did not receive intervention
Quality of Life Brief Assessment
Baseline (Time 1)
13.1 Score on a Scale
Standard Deviation 2.94
13.1 Score on a Scale
Standard Deviation 2.74
Quality of Life Brief Assessment
Post-intervention 1 (Time 2)
13.7 Score on a Scale
Standard Deviation 2.97
13.5 Score on a Scale
Standard Deviation 2.79
Quality of Life Brief Assessment
Post-intervention 2 (Time 3)
14.1 Score on a Scale
Standard Deviation 2.83
13.4 Score on a Scale
Standard Deviation 2.97

Adverse Events

Wellness Recovery Action Planning (WRAP)

Serious events: 0 serious events
Other events: 1 other events
Deaths: 4 deaths

Comparison Wait-List Group

Serious events: 0 serious events
Other events: 1 other events
Deaths: 6 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Wellness Recovery Action Planning (WRAP)
n=268 participants at risk
WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues. Wellness Recovery Action Planning (WRAP): WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
Comparison Wait-List Group
n=251 participants at risk
Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
Psychiatric disorders
Psychiatric Disorders
0.00%
0/268 • 3 years
0.40%
1/251 • Number of events 1 • 3 years

Additional Information

Judith A Cook

University of Illinois at Chicago

Phone: 312-355-3921

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place